CytomX Therapeutics (CTMX) AI Stock Analysis

• Market Cap: $694.28M
• Dividend Yield: N/A
• Average Volume (3M): 3.89M
• Price to Earnings (P/E): 7.3
• Beta (1Y): 2.79
• Revenue Growth: 18.01%
• EPS Growth: 306.76%
• Country: US
• Employees: 119
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 164,912,900
• 10 Day Avg. Volume: 3,335,194
• 30 Day Avg. Volume: 3,888,462
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $5.50
• Price Target Upside: 31.26% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: $4.00 ▼(-4.53% Downside)

CytomX Therapeutics shows promising clinical progress and a strong financial position, contributing positively to the stock score. Technical indicators suggest a strong uptrend, although caution is advised due to potential overbought conditions. The financial performance is mixed, with positive revenue growth but significant balance sheet and cash flow challenges. The valuation is attractive, but the lack of a dividend yield may deter some investors.

Positive Factors

Clinical Progress

The promising clinical data for CX-2051 indicates potential for successful treatment options in colorectal cancer, strengthening CytomX's product pipeline and market position in oncology.

Financial Position

A strong financial position with a significant cash runway allows CytomX to sustain its R&D efforts and operational activities, reducing financial risk and supporting long-term growth.

Revenue Growth

Consistent revenue growth reflects successful collaborations and product development, enhancing CytomX's ability to invest in future innovations and maintain competitive advantage.

Negative Factors

Balance Sheet Challenges

Negative equity indicates liabilities exceed assets, posing solvency risks that could limit financial flexibility and impact long-term sustainability.

Cash Flow Difficulties

Declining cash generation capabilities highlight challenges in funding operations and investments, potentially impacting CytomX's ability to capitalize on growth opportunities.

Revenue Decline

The decline in revenue due to completion of obligations with partners suggests potential volatility in income streams, which could affect financial stability and strategic planning.

CytomX Therapeutics Business Overview & Revenue Model

Company Description

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

How the Company Makes Money

CytomX Therapeutics generates revenue through a combination of collaborations, licensing agreements, and potential product sales. The company has established partnerships with major pharmaceutical firms, which often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future product sales. These collaborations allow CytomX to fund its research and development while sharing the financial risks associated with bringing new therapies to market. Additionally, if its Probody therapeutics successfully progress through clinical trials and receive regulatory approval, CytomX stands to earn significant revenue from the commercialization of these products.

CytomX Therapeutics Financial Statement Overview

Summary

CytomX Therapeutics has shown positive revenue growth and improved profitability margins, indicating operational recovery. However, negative equity, potential solvency risks, and cash flow difficulties present significant financial instability.

Income Statement

CytomX Therapeutics showed a positive revenue growth rate from 2023 to 2024, with total revenue increasing from $101.21 million to $138.10 million, representing a growth rate of approximately 36.4%. The gross profit margin remained strong at 100% due to no cost of goods sold. However, the net profit margin improved significantly in 2024, reaching approximately 23.1%, compared to a negative margin in 2023. The EBIT and EBITDA margins also turned positive, indicating improved operational efficiency. Despite these improvements, historical volatility and past losses present a risk.

Balance Sheet

The balance sheet reflects a concerning negative equity position in 2024, with stockholders' equity at -$456,000, indicating liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity, but total debt decreased over the year. The equity ratio is negative, which poses a significant risk to financial stability. This indicates potential solvency issues despite reducing total debt.

Cash Flow

The cash flow statement shows a deterioration in free cash flow from -$56.88 million in 2023 to -$86.54 million in 2024, indicating a decline in cash generation capabilities. The operating cash flow to net income ratio is negative, suggesting challenges in converting income into cash. Free cash flow to net income is also negative, highlighting cash flow difficulties despite positive net income in 2024. The high variability in cash flows suggests potential liquidity issues.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	138.10M	101.21M	53.16M	69.57M	100.36M
Gross Profit	138.10M	101.21M	47.31M	63.73M	100.36M
EBITDA	26.76M	-4.31M	-98.89M	-113.34M	-77.97M
Net Income	31.87M	-569.00K	-97.30M	-80.65M	-32.88M
Balance Sheet
Total Assets	120.53M	201.79M	260.89M	339.41M	358.66M
Cash, Cash Equivalents and Short-Term Investments	100.62M	174.51M	193.65M	305.23M	316.12M
Total Debt	9.38M	13.97M	18.06M	18.06M	24.87M
Total Liabilities	120.99M	249.24M	346.64M	250.03M	308.86M
Stockholders Equity	-456.00K	-47.45M	-85.75M	89.38M	49.80M
Cash Flow
Free Cash Flow	-86.54M	-56.88M	-112.53M	-120.64M	2.95M
Operating Cash Flow	-86.23M	-56.03M	-110.79M	-119.03M	5.26M
Investing Cash Flow	99.70M	-150.67M	98.26M	22.49M	-18.72M
Financing Cash Flow	7.52M	30.23M	648.00K	110.21M	16.89M

CytomX Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.19
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTMX, the sentiment is Positive. The current price of 4.19 is above the 20-day moving average (MA) of 3.53, above the 50-day MA of 2.91, and above the 200-day MA of 1.86, indicating a bullish trend. The MACD of 0.29 indicates Negative momentum. The RSI at 73.70 is Negative, neither overbought nor oversold. The STOCH value of 80.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTMX.

CytomX Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	66 Neutral	$694.28M	7.33	108.21%	―	18.01%	306.76%
LXRX	55 Neutral	$483.32M	-3.99	-65.30%	―	1504.83%	56.81%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KALV	45 Neutral	$543.63M	―	-190.18%	―	―	-13.14%
VSTM	44 Neutral	$544.89M	―	-2888.70%	―	33.79%	-26.37%
ARCT	42 Neutral	$242.49M	-4.02	-24.57%	―	-26.88%	13.41%
BCYC	41 Neutral	$427.62M	―	-34.63%	―	-23.43%	-9.84%

CytomX Therapeutics Corporate Events

CytomX Therapeutics Advances CX-2051 Study in Solid Tumors

Study Overview: CytomX Therapeutics Inc. is conducting a first-in-human study titled ‘An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors.’ The study aims to assess the safety, tolerability, and antitumor activity of CX-2051 in adults with advanced solid tumors, marking a significant step in cancer treatment research.

CytomX Therapeutics Updates on CX-2051 Phase 1 Study

On August 13, 2025, CytomX Therapeutics announced an update on its CX-2051 Phase 1 study, detailing dose expansions and a treatment-related incident. Despite a Grade 5 acute kidney injury in a patient, the study continues with support from the Safety Review Committee, and a data update is expected by Q1 2026.

The most recent analyst rating on (CTMX) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on CytomX Therapeutics stock, see the CTMX Stock Forecast page.

CytomX Therapeutics Earnings Call: Clinical Progress and Financial Strength

CytomX Therapeutics Inc. recently held its earnings call, revealing a sentiment of cautious optimism. The company showcased significant clinical progress, particularly with its CX-2051 program, and emphasized its strong financial position. Despite a decrease in revenue and some adverse events in trials, the call highlighted focused pipeline development and strategic financial planning as positive aspects.

CytomX Therapeutics Reports Strong Financial Turnaround

CytomX Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies using its proprietary PROBODY technology platform, which enables conditional activation of therapeutics in the tumor microenvironment. In its latest earnings report for the quarter ended June 30, 2025, CytomX Therapeutics highlighted a significant improvement in its financial performance. The company reported revenues of $18.7 million for the quarter, a decrease from $25.1 million in the same period last year, but achieved a net income of $23.4 million for the first half of 2025, compared to $7.3 million in the first half of 2024. This improvement was driven by reduced operating expenses and strategic collaborations. Key financial metrics included a reduction in research and development expenses to $13.3 million from $25.2 million in the previous year and a decrease in general and administrative expenses. The company also reported a strong cash position with cash and cash equivalents of $49 million, bolstered by a successful follow-on offering. Looking ahead, CytomX Therapeutics remains focused on advancing its clinical programs and leveraging strategic partnerships to drive future growth, as it continues to innovate in the oncology sector.